One-third of patients with PSA levels below 0.2 ng/mL after radical prostatectomy have recurrent disease identifiable by PSMA PET. More than one-third of patients with PSA levels less than 0.5 ng/mL ...

He remains symptom-free. The treatment is now approved for more patients. The randomized trial in 468 patients showed that 177 Lu-PSMA-617 prolonged progression-free survival (the period when the ...

The antibody 7E11 binds to the intracellular epitope of PSMA and can reach this only when the cell membrane is damaged. In this case, the tumor on the right was irradiated; the left one was not. The ...

Shuttle Pharma seeks US patent for PSMA Ligand Conjugates to treat prostate cancer: Gaithersburg, Maryland Monday, April 14, 2025, 16:00 Hrs [IST] Shuttle Pharmaceuticals Holdings ...

By focusing on a non-PSMA target, we also believe ATNM-400 has ... survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition, Actinium is engaged with the National Cancer ...